Quantifying the tumor microenvironment: what is the next step to advance cancer immunotherapy?
Immuno-Oncology Insights 2022; 3(4), 93–97
10.18609/ioi.2022.012
Published: 27 March 2022
Commentary
Ning Wang
“Identifying the cancer type and patient cohort
that could potentially respond to an oncology
drug is one of the most important questions in
oncology drug development. Thus, profiling and
quantifying the TME in a cancer type specific
manner is critical.”
